Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017

Eine Wissenschaftlerin im Labor. (Symbolbild). © gevende / E+ / Getty Images

PR Newswire

CRANBURY, N.J., Dec. 29, 2016

CRANBURY, N.J., Dec. 29, 2016 /PRNewswire/ --

WHAT: Cornerstone Pharmaceuticals will present to investors and biopharmaceutical executives from around the world. The 9^th Annual Conference Biotech Showcase™ is one of the largest annual healthcare conferences around the world and will take place in San Francisco concurrently to the J.P. Morgan 35^th Annual Healthcare Conference. Members of Cornerstone's management team will present information on its Altered Energy Metabolism Directed (AEMD) platform, update on clinical trials for its lead compound CPI-613, and future strategy.

Interviews prior and during the conference available upon request:

Presenters:
- Sanjeev Luther, Chief Operating Officer, Cornerstone Pharmaceuticals
- Timothy S. Pardee, MD, PhD, Chief Oncologist, Cornerstone Pharmaceuticals
Board Members:
- Howard Jonas, Chairman of the Board, Cornerstone Pharmaceuticals
- Jean-Pierre Sommadossi, PhD, Principal Founder, Chairman and CEO of Atea Pharmaceuticals, Vice Chairman of Cornerstone Pharmaceuticals Board of Directors

WHERE: 9^thAnnual Conference Biotech Showcase, Hilton San Francisco Union Square, San Francisco, California

WHEN: January 11, 2017, 2:30 – 3:00pm PT

CONTACT: Kara Golub, 609-456-0822 or kgolub@jfkhealth.com, for more information.

About Cornerstone Pharmaceuticals, Inc.

ARIVA.DE Börsen-Geflüster

Kurse

IDT

36,59 $

0,00%

Cornerstone Pharmaceuticals, Inc. is a privately held, clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's investors include IDT Corporation (NYSE: IDT). Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). www.cornerstonepharma.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-to-present-at-9th-annual-biotech-showcase-in-san-francisco-january-9-11-2017-300384099.html

SOURCE Cornerstone Pharmaceuticals, Inc.

Mehr Nachrichten zur IDT Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.